Die Innovative Medicines Initiative 2 (IMI 2) hat ihre 15. und 16. Ausschreibungsrunde geöffnet.

Die 15. IMI 2-Ausschreibung umfasst die folgenden Themen:

• Topic 1: Integrated research platforms enabling patient-centric drug development
• Topic 2: Blockchain Enabled Healthcare
• Topic 3: Microenvironment imposed signatures in tissue and liquid biopsies in immune-mediated diseases
• Topic 4: Emerging translational safety technologies and tools for interrogating human immuno-biology
• Topic 5: Development and validation of translational platforms in support of synaptopathy drug discovery
• Topic 6: Digital endpoints in neurodegenerative and immune-mediated diseases

Hinzu kommen noch zwei weitere Themen aus dem neu gestarteten Antimicrobial Resistance (AMR) Accelerator Programme:

• Topic 7: AMR Accelerator programme Pillar A: Capability Building Network to accelerate and validate scientific discoveries
• Topic 8: AMR Accelerator programme Pillar B: Tuberculosis drug development network to accelerate and validate scientific discoveries and advance the R&D pipeline of new and innovative agents to address the global tuberculosis epidemic

Die 16. IMI 2-Ausschreibung umfasst die folgenden Themen:

• Topic 1: Progress new assets (one pre-new molecular entity (preNME) and one first-time-in-human (FTIH) start) for tuberculosis (TB) that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors
• Topic 2: Progress novel assets (one FTIH start) for non-tubercular mycobacteria (NTM) that may act synergistically with bedaquiline and cytochrome bc drugs
• Topic 3: Discover and progress novel assets with new mechanisms of action (one preNME for TB and one preNME for NTM) and biomarkers for TB and NTM infection
• Topic 4: Determination of gepotidacin levels in tonsils and prostatic tissue
• Topic 5: Infection site targeting, antibiotic encapsulated in nanoparticles for treating extracellular bacterial infections
• Topic 6: Functional Ethionamide boosters: a novel combination for tuberculosis therapy
• Topic 7: Intravenous treatments of serious infections (urinary tract infections (UTI), intra-abdominal infections (IAI) & hospital-acquired pneumonia/ventilator associated pneumonia (HAP/VAP)) caused by Gram(-) bacteria (Enterobacteriaceae +/- Pseudomonas and/or Acinetobacter)

Termin: 24.10.2018
Weitere Informationen zu den einzelnen Ausschreibungen: 15. Runde, 16. Runde